PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24173426-6	2014	The blaNDM-1-harbouring plasmids conferred antimicrobial resistance to carbapenems, cephalosporins, aminoglycosides and aztreonam in transconjugants.	Aztreonam	120-129	metallo-beta-lactamase NDM-1	Klebsiella pneumoniae	4-12
25059447-4	2014	Multilocus sequence typing (MLST) revealed that all NDM-1-producing K. pneumoniae isolates belonged to sequence type 340 (ST340) and harboured genes encoding additional beta-lactamases; presence of the bla(CTX-M-1-like) gene correlated with aztreonam resistance, whilst its absence correlated with susceptibility.	Aztreonam	241-250	NDM-1	Klebsiella pneumoniae	52-57
24789185-0	2014	Incidence of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.	Aztreonam	152-161	EsbL	Escherichia coli	13-45
24789185-1	2014	The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated.	Aztreonam	17-26	EsbL	Escherichia coli	112-144
24789185-1	2014	The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated.	Aztreonam	17-26	EsbL	Escherichia coli	146-150
24789185-2	2014	Our analysis showed that results for aztreonam and/or >=1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBL-producing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).	Aztreonam	37-46	EsbL	Escherichia coli	133-137
24789185-2	2014	Our analysis showed that results for aztreonam and/or >=1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBL-producing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).	Aztreonam	37-46	EsbL	Escherichia coli	196-200
19664245-0	2009	In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.	Aztreonam	34-43	Beta lactamase	Pseudomonas aeruginosa	132-146
24033858-4	2013	MICs to beta-lactams in E. coli W4573 and its acrAB mutant strain increased 1- to 500-fold (MIC from 0.125 to 64 mug mL(-1) of aztreonam) in the bla(KPC-2a), bla(KPC-2b), and bla(KPC-2c) transformants compared with the cloning vector alone.	Aztreonam	127-136	TEM beta-lactamase	Klebsiella pneumoniae	145-148
24033858-4	2013	MICs to beta-lactams in E. coli W4573 and its acrAB mutant strain increased 1- to 500-fold (MIC from 0.125 to 64 mug mL(-1) of aztreonam) in the bla(KPC-2a), bla(KPC-2b), and bla(KPC-2c) transformants compared with the cloning vector alone.	Aztreonam	127-136	TEM beta-lactamase	Klebsiella pneumoniae	158-161
24033858-4	2013	MICs to beta-lactams in E. coli W4573 and its acrAB mutant strain increased 1- to 500-fold (MIC from 0.125 to 64 mug mL(-1) of aztreonam) in the bla(KPC-2a), bla(KPC-2b), and bla(KPC-2c) transformants compared with the cloning vector alone.	Aztreonam	127-136	TEM beta-lactamase	Klebsiella pneumoniae	158-161
19664245-0	2009	In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.	Aztreonam	85-94	Beta lactamase	Pseudomonas aeruginosa	132-146
19664245-6	2009	RESULTS: Bacteriostatic effects after 6 hours of drug exposure were observed in 12 strains (52.2%) of 23 strains of metallo-beta-lactamase-producing P. aeruginosa with 48 mg/l aztreonam, in 19 strains (82.6%) with the 3-drug combination of 16 mg/l aztreonam, 16 mg/l ceftazidime, and 4 mg/l amikacin, and in 23 strains (100%) with 2 mg/l colistin.	Aztreonam	176-185	Beta lactamase	Pseudomonas aeruginosa	124-138
19664245-8	2009	CONCLUSION: Evaluation of in vitro antimicrobial effects on metallo-beta-lactamase-producing P. aeruginosa revealed relatively good effects of the 3-drug combination of aztreonam, ceftazidime and amikacin and marked effects of colistin.	Aztreonam	169-178	Beta lactamase	Pseudomonas aeruginosa	68-82
19258280-4	2009	The inactivation of the mexB gene (which codes for the RND transporter MexB) in the 11 selected strains showed that the Tic(hs) phenotype was due to a mutational or functional loss of function of MexAB-OprM, the multidrug efflux system known to contribute to the natural resistance of P. aeruginosa to beta-lactams (e.g., ticarcillin and aztreonam), fluoroquinolones, tetracycline, and novobiocin.	Aztreonam	338-347	multidrug resistance protein MexB	Pseudomonas aeruginosa PAO1	24-28
19258280-4	2009	The inactivation of the mexB gene (which codes for the RND transporter MexB) in the 11 selected strains showed that the Tic(hs) phenotype was due to a mutational or functional loss of function of MexAB-OprM, the multidrug efflux system known to contribute to the natural resistance of P. aeruginosa to beta-lactams (e.g., ticarcillin and aztreonam), fluoroquinolones, tetracycline, and novobiocin.	Aztreonam	338-347	multidrug resistance protein MexB	Pseudomonas aeruginosa PAO1	71-75
18692340-3	2008	Ninety-one percent of laboratories recognized all ESBL producers correctly, and therefore, low error rates were observed when testing cephalosporins and aztreonam.	Aztreonam	153-162	EsbL	Escherichia coli	50-54
19388560-7	2009	Among the ESBL-producing isolates, the sensitivity was from 3.3% to 61.5% for ampicillin to aztreonam.	Aztreonam	92-101	EsbL	Escherichia coli	10-14
18079018-5	2008	VIM-2-positive strains were mostly from urine samples and clinical data suggest that in the absence of therapeutic guidelines, piperacillin-tazobactam or aztreonam may be a reliable choice for treating infections with MBL-producing strains.	Aztreonam	154-163	VIM-2	Pseudomonas aeruginosa	0-5
18644957-3	2008	The bla(VIM-13)-producing isolate showed resistance to all beta-lactams (except aztreonam), gentamicin, tobramycin, and ciprofloxacin.	Aztreonam	80-89	Beta lactamase	Pseudomonas aeruginosa	4-7
18184647-1	2008	OBJECTIVES: Twenty-four of 209 oxyimino-cephalosporin- and/or aztreonam-resistant Enterobacteriaceae collected around Bolzano had reduced susceptibility or resistance to carbapenems and gave positive metallo-beta-lactamase (MBL) tests.	Aztreonam	62-71	NDM-1	Escherichia coli	200-222
18184647-1	2008	OBJECTIVES: Twenty-four of 209 oxyimino-cephalosporin- and/or aztreonam-resistant Enterobacteriaceae collected around Bolzano had reduced susceptibility or resistance to carbapenems and gave positive metallo-beta-lactamase (MBL) tests.	Aztreonam	62-71	NDM-1	Escherichia coli	224-227
18379184-10	2008	Aztreonam and ciprofloxacin were then intravenously administered at doses of 4 g/day and 600 mg/day, respectively, resulting in the alleviation of fever in the patient as well as a decrease in CRP and disappearance of MDRP isolates from urine on day 67; that is, MDRP infection was consequently well controlled.	Aztreonam	0-9	C-reactive protein	Homo sapiens	193-196
18184647-9	2008	Six MBL producers were aztreonam-susceptible; the 18 aztreonam-resistant isolates had co-resident extended-spectrum beta-lactamases.	Aztreonam	23-32	NDM-1	Escherichia coli	4-7
16678993-4	2006	High rates of very major errors (up to 56%) were observed for ESBL producers when testing cephalosporins and aztreonam, especially in the case of CTX-M-1-producing Escherichia coli and TEM-52-producing Proteus mirabilis.	Aztreonam	109-118	EsbL	Escherichia coli	62-66
18059098-9	2008	Over 90% of ESBL isolates showed resistance to aztreonam and cephalosporins.	Aztreonam	47-56	EsbL	Escherichia coli	12-16
17223016-0	2007	Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.	Aztreonam	48-57	beta-lactamase	Klebsiella pneumoniae	112-126
15815007-4	2005	The strains were screened for the production of extended-spectrum beta-lactamase (ESBL) by the double-disk synergy test using a disk of amoxicillin-clavulanic acid with disks of the extended-spectrum cephalosporins and aztreonam.	Aztreonam	219-228	EsbL	Escherichia coli	48-80
15629222-4	2005	The ESBL-positive K. pneumoniae isolates were resistant to aztreonam, ceftazidime, aminoglycosides, and trimethoprim/sulfamethoxazole and susceptible to ciprofloxacin and tetracycline.	Aztreonam	59-68	CTX-M-15	Klebsiella pneumoniae	4-8
15743578-1	2005	INTRODUCTION: In the last years, we have verified the increasing emergence of bacteria, specially Escherichia coli, that produce expanded spectrum beta-lactamases (ESBL), enzymes which confer resistance to all cephalosporins (except cephamycins) and aztreonam.	Aztreonam	250-259	EsbL	Escherichia coli	164-168
12951239-7	2003	Clavulanic acid had no inhibitory effect on Mox-1 (K(m)=30.2 mM), however aztreonam behaved as an inhibitor of Mox-1 (K(i)=2.85 microM).	Aztreonam	74-83	mesenchyme homeobox 1	Homo sapiens	111-116
15155242-1	2004	A clinical strain of Escherichia coli isolated from pleural liquid with high levels of resistance to cefotaxime, ceftazidime, and aztreonam harbors a novel CTX-M gene (bla(CTX-M-32)) whose amino acid sequence differs from that of CTX-M-1 by a single Asp240-Gly substitution.	Aztreonam	130-139	beta-lactamase	Escherichia coli	168-171
15155242-1	2004	A clinical strain of Escherichia coli isolated from pleural liquid with high levels of resistance to cefotaxime, ceftazidime, and aztreonam harbors a novel CTX-M gene (bla(CTX-M-32)) whose amino acid sequence differs from that of CTX-M-1 by a single Asp240-Gly substitution.	Aztreonam	130-139	CTX-M-1	Escherichia coli	230-237
14638498-7	2003	The bla(KPC-2) determinant was cloned in E. coli and conferred resistance to imipenem, meropenem, extended-spectrum cephalosporins, and aztreonam.	Aztreonam	136-145	KPC-2	Escherichia coli	8-13
14638498-9	2003	Hydrolysis studies showed that purified KPC-2 hydrolyzed not only carbapenems but also penicillins, cephalosporins, and aztreonam.	Aztreonam	120-129	KPC-2	Escherichia coli	40-45
12909725-7	2003	We demonstrate that our error-prone Pol I can be used to generate enzymes with distinct properties by generating TEM-1 beta-lactamase mutants able to hydrolyze a third-generation lactam antibiotic, aztreonam.	Aztreonam	198-207	TEM-1 beta-lactamase	Escherichia coli	113-133
12615876-4	2003	Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum beta-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam).	Aztreonam	253-262	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	13-18
12507831-11	2003	Among Enterobacter spp., resistance (MIC>or=32 mg/l) to aztreonam, ceftazidime and ceftriaxone ranged from 12.3 to 21.2% over the 4 years, whereas resistance in Klebsiella (MIC>or=2 mg/l) ranged from 5.9 to 6.8%.	Aztreonam	59-68	histocompatibility minor 13	Homo sapiens	19-22
12532575-6	2002	Isolates resistant to cefpodoxime and aztreonam were considered as ESBL phenotype, indicating ESBL production.	Aztreonam	38-47	EsbL	Escherichia coli	67-71
12935353-2	2003	Ceftazidime and aztreonam enhanced TNF-alpha secretion from macrophages stimulated with E. coli; however, imipenem does not alter either the kinetics or magnitude of TNF-alpha in E. coli-treated macrophages.	Aztreonam	16-25	tumor necrosis factor	Mus musculus	35-44
12935353-6	2003	Both ceftazidime and aztreonam enhanced LPS release from E. coli in comparison to low-level LPS release from imipenem-treated bacteria, consistent with observed differences in TNF-alpha release.	Aztreonam	21-30	tumor necrosis factor	Mus musculus	176-185
12532575-6	2002	Isolates resistant to cefpodoxime and aztreonam were considered as ESBL phenotype, indicating ESBL production.	Aztreonam	38-47	EsbL	Escherichia coli	94-98
12532575-14	2002	Resistance to both cefpodoxime and aztreonam was found in 25% isolates suggesting ESBL production.	Aztreonam	35-44	EsbL	Escherichia coli	82-86
11376058-7	2001	Thus, it is clinically important to detect ESBL production by klebsiellae or E. coli even when cephalosporin MICs are in the susceptible range (<or = 8 microg/ml) and to report ESBL-producing organisms as resistant to aztreonam and all cephalosporins (with the exception of cephamycins).	Aztreonam	221-230	EsbL	Escherichia coli	43-47
11929691-8	2002	Overall, ceftriaxone and aztreonam were the best substrates for the detection of the ESBL phenotype between both E. coli isolates and K. pneumoniae ESBL phenotypes; however, there was significant variation between countries in substrate preference.	Aztreonam	25-34	EsbL	Escherichia coli	85-89
11929691-8	2002	Overall, ceftriaxone and aztreonam were the best substrates for the detection of the ESBL phenotype between both E. coli isolates and K. pneumoniae ESBL phenotypes; however, there was significant variation between countries in substrate preference.	Aztreonam	25-34	EsbL	Escherichia coli	148-152
11442343-2	2001	Of the 668 isolates, the 80 strains were presumptively defined as ESBL producers according to the result of disk method using ESBL marker antibiotics (aztreonam, ceftazidime, and cefoxitin).	Aztreonam	151-160	EsbL	Escherichia coli	66-70
11794541-3	2001	Analysis of this strain by the double disk diffusion test showed synergies between amoxicillin-clavulanate (AMX-CA) and cefotaxime, and AMX-CA and aztreonam, which suggested that this strain produced a extended-spectrum beta-lactamase (ESBL).	Aztreonam	147-156	CTX-M-15	Klebsiella pneumoniae	202-234
9705395-0	1998	Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?	Aztreonam	241-250	beta-lactamase	Escherichia coli	105-119
11320450-2	2001	The highest percentage of ESBL phenotype (defined as a minimum inhibitory concentration [MIC] > or =2 microg/mL for ceftazidime, ceftriaxone, or aztreonam) was detected among K. pneumoniae strains from Latin America (45%), followed by those from the Western Pacific region (25%), Europe (23%), the United States (8%), and Canada (5%).	Aztreonam	148-157	CTX-M-15	Klebsiella pneumoniae	26-30
11257029-8	2001	The gene, bla(KPC-1), was cloned in E. coli and shown to confer resistance to imipenem, meropenem, extended-spectrum cephalosporins, and aztreonam.	Aztreonam	137-146	beta-lactamase	Escherichia coli	10-13
11036023-1	2000	Serratia marcescens Rio-5, one of 18 extended-spectrum beta-lactamase (ESBL)-producing strains isolated in several hospitals in Rio de Janeiro (Brazil) in 1996 and 1997, exhibited a high level of resistance to aztreonam (MIC, 512 microgram/ml) and a distinctly higher level of resistance to cefotaxime (MIC, 64 microgram/ml) than to ceftazidime (MIC, 8 microgram/ml).	Aztreonam	210-219	BES-1	Serratia marcescens	37-69
11036023-1	2000	Serratia marcescens Rio-5, one of 18 extended-spectrum beta-lactamase (ESBL)-producing strains isolated in several hospitals in Rio de Janeiro (Brazil) in 1996 and 1997, exhibited a high level of resistance to aztreonam (MIC, 512 microgram/ml) and a distinctly higher level of resistance to cefotaxime (MIC, 64 microgram/ml) than to ceftazidime (MIC, 8 microgram/ml).	Aztreonam	210-219	BES-1	Serratia marcescens	71-75
11036023-6	2000	However, BES-1 differed from CTX-M enzymes by its significant ceftazidime-hydrolyzing activity (k(cat), 25 s(-1)), high affinity for aztreonam (K(i), 1 microM), and lower susceptibility to tazobactam (50% inhibitory concentration [IC(50)], 0.820 microM) than to clavulanate (IC(50), 0.045 microM).	Aztreonam	133-142	BES-1	Serratia marcescens	9-14
10705053-3	2000	Isolates with intermediate or resistant susceptibilities for extended spectrum cephalosporins or aztreonam were reported as probable ESBL producers.	Aztreonam	97-106	EsbL	Escherichia coli	133-137
10926441-3	2000	Different dosages of aztreonam injected into mice induced an increase in the lymphoproliferative response to specific mitogens and in the production of interleukin-2 by splenic cells, as well as a decreased response of this immune population to sheep erythrocytes lower total blood cell counts and a lower percentage of monocytes than in untreated mice.	Aztreonam	21-30	interleukin 2	Mus musculus	152-165
9835525-9	1998	The addition of CAP18106-137 to aztreonam along with the bacteria did decrease the level of antibiotic-induced release of inflammatory mediators including tumor necrosis factor alpha, interleukin-6, and nitric oxide and also improved the survival of the mice.	Aztreonam	32-41	tumor necrosis factor	Mus musculus	155-182
9835525-9	1998	The addition of CAP18106-137 to aztreonam along with the bacteria did decrease the level of antibiotic-induced release of inflammatory mediators including tumor necrosis factor alpha, interleukin-6, and nitric oxide and also improved the survival of the mice.	Aztreonam	32-41	interleukin 6	Mus musculus	184-197
9371336-4	1997	The purified enzyme was studied from a kinetic point of view, revealing the highest catalytic efficiency (k[cat]/Km) values for ceftazidime and aztreonam compared with the TEM-1 prototype enzyme.	Aztreonam	144-153	TEM-1	Serratia marcescens	172-177
9687393-6	1998	Transformants producing only the pI 8.8 beta-lactamase were resistant to cefotaxime and aztreonam but were susceptible or intermediate to ceftazidime.	Aztreonam	88-97	Bla	Salmonella enterica subsp. enterica serovar Typhimurium	40-54
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Aztreonam	34-43	myeloperoxidase	Mus musculus	57-60
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Aztreonam	34-43	tumor necrosis factor	Mus musculus	93-102
9529499-9	1998	Both continuous metronidazole and aztreonam reduced lung MPO concentration (P < 0.05) and TNF-alpha and IL-1 beta mRNA expression (P < 0.05) compared with those in saline controls.	Aztreonam	34-43	interleukin 1 beta	Mus musculus	107-116
9593123-1	1998	A TEM-1 beta-lactamase derivative containing the single amino acid substitution A237T slightly increased (from 24 to 32 microg/ml) the cephalothin MIC for Escherichia coli RYC1000 but did not influence the activities of cefotaxime, ceftazidime, and aztreonam (MICs of 0.03, 0.12, and 0.06 microg/ml, respectively).	Aztreonam	249-258	TEM-1 beta-lactamase	Escherichia coli	2-22
1384868-9	1992	Furthermore, the MAb showed no inhibitory reaction with various beta-lactams except aztreonam- and ceftazidime-EACA conjugates in the ELISA inhibition test, suggesting that Az-3 recognize a new antigenic determinant (NAD), which is formed by the conjugation of beta-lactam and carrier protein.	Aztreonam	84-93	ornithine decarboxylase antizyme 3	Homo sapiens	173-177
8851581-2	1996	Salmonella typhimurium JMC isolated in Argentina harbors a bla gene located on a plasmid (pMVP-5) which confers transferable resistance to oxyiminocephalosporins, aztreonam, and ceftibuten.	Aztreonam	163-172	Bla	Salmonella enterica subsp. enterica serovar Typhimurium	59-62
7694816-10	1993	Interestingly, simultaneous injection of Aztreonam with rG-CSF significantly enhanced the effect of rG-CSF on the PMN functions.	Aztreonam	41-50	colony stimulating factor 3	Rattus norvegicus	100-106
1499375-3	1992	Aztreonam showed a high affinity to chromosomal-mediated cephalosporinase P99, its Ki for inhibition of P99 with cephaloridine as substrate was 0.0159 microns.	Aztreonam	0-9	protein phosphatase 1 regulatory subunit 10	Homo sapiens	74-77
1499375-3	1992	Aztreonam showed a high affinity to chromosomal-mediated cephalosporinase P99, its Ki for inhibition of P99 with cephaloridine as substrate was 0.0159 microns.	Aztreonam	0-9	protein phosphatase 1 regulatory subunit 10	Homo sapiens	104-107
9011117-0	1996	Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.	Aztreonam	94-103	colony stimulating factor 3	Homo sapiens	28-65
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Aztreonam	165-174	colony stimulating factor 3	Homo sapiens	88-125
9011117-1	1996	The present multicenter study was performed to evaluate the effect of recombinant human granulocyte-colony stimulating factor (rhG-CSF) on combination therapy using aztreonam (AZT) and clindamycin (CLDM) to treat severe infection in neutropenic patients with hematologic diseases.	Aztreonam	176-179	colony stimulating factor 3	Homo sapiens	88-125
7695296-8	1995	Interestingly, the change from Gln to Lys at position 39 found in TEM-2, classically considered a neutral change, slightly but consistently increased the MIC of ceftazidime and aztreonam.	Aztreonam	177-186	RASD family member 2	Homo sapiens	66-71
8071678-3	1994	Aztreonam induces dose-dependent phagocytosis up to 25 micrograms/ml concentrations; with a phagocytosis index (PIa) of 1.18 +/- 0.2 at 1 microgram/ml; of 1.27 +/- 0.2 at 10 micrograms/ml; of 1.42 +/- 0.3 at 25 micrograms/ml.	Aztreonam	0-9	RPTOR independent companion of MTOR complex 2	Homo sapiens	112-115
8486571-5	1993	However, after incubation for 24 h, a significant rise in TNF production was noticed in the cefuroxime and aztreonam-treated cultures (6440 and 5969 ng/L, respectively) compared to the ceftazidime and imipenem-treated cultures (846 and 381 ng/L, respectively).	Aztreonam	107-116	tumor necrosis factor	Homo sapiens	58-61
8486571-10	1993	The differences in TNF production between these antibiotics could be explained by the production of filaments following treatment with cefuroxime, aztreonam and low-dose ceftazidime, resulting in late bacterial lysis with high levels of endotoxin, whereas treatment with imipenem or high-dose ceftazidime resulted in the formation of spheroplasts, resulting in early lysis of the bacteria and much lower levels of endotoxin.	Aztreonam	147-156	tumor necrosis factor	Homo sapiens	19-22
8486571-11	1993	The addition of taurolidine to either imipenem or aztreonam-treated cultures prevented a rise in TNF production as a result of nearly complete neutralization of the released endotoxin.	Aztreonam	50-59	tumor necrosis factor	Homo sapiens	97-100
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	0-9	Beta lactamase	Pseudomonas aeruginosa	55-69
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	0-9	Beta lactamase	Pseudomonas aeruginosa	120-134
1590704-5	1992	Aztreonam therapy lead to opposite results because the beta-lactamase activity decreased and aztreonam was able to mask beta-lactamase activity by acting as an inhibitor.	Aztreonam	93-102	Beta lactamase	Pseudomonas aeruginosa	120-134
1384868-1	1992	Three cell lines producing monoclonal antibodies, Az-1 (IgG1), Az-2 (IgG1) and Az-3 (IgM) against aztreonam were established.	Aztreonam	98-107	ornithine decarboxylase antizyme 3	Homo sapiens	79-83
1384868-3	1992	In ELISA, Az-1 and Az-2 reacted only with aztreonam and ceftazidime, which have the same acyl side chain.	Aztreonam	42-51	centrosomal protein 131	Homo sapiens	10-23
1894940-7	1991	Ceftazidime, aztreonam, and cefotaxime killed E. coli at a slower rate and were associated with significant increases in mononuclear cell TNF responses.	Aztreonam	13-22	tumor necrosis factor	Homo sapiens	138-141
1384868-5	1992	In the ELISA inhibition test, Az-1 and Az-2 were inhibited from binding to aztreonam-HSA by aztreonam, ceftazidime, aztreonam hydrolysate, aztreonam-epsilon-amino-n-caproic acid (EACA) and ceftazidime-EACA.	Aztreonam	75-84	centrosomal protein 131	Homo sapiens	30-34
1384868-5	1992	In the ELISA inhibition test, Az-1 and Az-2 were inhibited from binding to aztreonam-HSA by aztreonam, ceftazidime, aztreonam hydrolysate, aztreonam-epsilon-amino-n-caproic acid (EACA) and ceftazidime-EACA.	Aztreonam	75-84	ornithine decarboxylase antizyme 2	Homo sapiens	39-43
2282121-1	1990	The substituted 3-aminoxyproprionyl (VII) and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams (VIII) which possess the monocyclic beta-lactam nucleus of aztreonam (IX) were synthesized by reaction of triethylammonium (3S, 4S)-3-amino-4-methyl-2-oxo-1-azetidinsulfonate with the aminoxy acids X and XI, respectively.	Aztreonam	155-164	cytochrome c oxidase subunit 8A	Homo sapiens	97-101
2063887-2	1991	Advantages of aztreonam over the aminoglycosides include lack of ototoxicity and nephrotoxicity and better penetration into the CSF.	Aztreonam	14-23	colony stimulating factor 2	Homo sapiens	128-131
2081716-8	1990	These results indicated that the mechanisms that confer non-beta-lactamase-mediated insusceptibility to penicillins, cephalosporins and aztreonam in H. influenzae have little or no effect on susceptibility to carbapenems.	Aztreonam	136-145	beta-lactamase TEM-1	Haemophilus influenzae	60-74
2258651-3	1990	The resistance pattern against various beta-lactams and the effects on MICs of combination of Clavulanic acid (CVA) and AZT against AZT resistant strains suggested that AZT was inactivated by either type of IV (K1), Va (OXA1), or PSE2 beta-lactamases.	Aztreonam	120-123	OXA1L mitochondrial inner membrane protein	Homo sapiens	220-224
2282121-4	1990	On the contrary VII and VIII proved to be practically inactive against Gram-negative microorganisms, towards which aztreonam exhibits a high degree of activity.	Aztreonam	115-124	cytochrome c oxidase subunit 8A	Homo sapiens	24-28
2506109-0	1989	Substitution of serine for arginine in position 162 of TEM-type beta-lactamases extends the substrate profile of mutant enzymes, TEM-7 and TEM-101, to ceftazidime and aztreonam.	Aztreonam	167-176	plexin domain containing 1	Homo sapiens	129-134
2199628-1	1990	We have compared the effects of aztreonam and placebo in the prevention of urinary tract infections (UTI) in elderly hospitalized patients who needed urethral catheterization.	Aztreonam	32-41	alpha-1-microglobulin/bikunin precursor	Homo sapiens	101-104
2199628-6	1990	At the end of follow-up 71/80 patients (88.7%) who received a single preventing dose of aztreonam had negative urine culture without clinical signs of UTI.	Aztreonam	88-97	alpha-1-microglobulin/bikunin precursor	Homo sapiens	151-154
2199628-9	1990	dose of aztreonam is effective in preventing UTI in elderly patients needing indwelling urethral catheterization.	Aztreonam	8-17	alpha-1-microglobulin/bikunin precursor	Homo sapiens	45-48
2374296-15	1990	Transient elevations of GOT and GPT were seen in 2 cases when AZT administration was continued at length.	Aztreonam	62-65	glutamic--pyruvic transaminase	Homo sapiens	32-35
2362356-2	1990	After intravenous injection of 1 g AZT, it was found that serum AZT concentrations during hemodialysis were different from those during nonhemodialysis and serum half-lives (T 1/2 beta) were 3.44 hours and 16.97 hours, respectively.	Aztreonam	35-38	interleukin 1 receptor like 1	Homo sapiens	174-184
34113134-10	2021	High rates of bla TEM, bla CTX-M-1, and bla CTX-M-9 were consistent with the poor activity of third-generation cephalosporins and aztreonam in vitro, except for carbapenem and beta-lactamase inhibitor combinations.	Aztreonam	130-139	CTX-M-1	Escherichia coli	27-34
33806340-5	2021	A significant association (p value < 0.05) was observed between the multidrug efflux pump (AcrA) and resistance to beta-lactams and the aminoglycoside acetyl transferase gene (aac-6"-Ib) gene and resistance to ciprofloxacin, azithromycin and beta-lactams (except for aztreonam).	Aztreonam	267-276	aminoglycoside N(6')-acetyltransferase	Klebsiella pneumoniae	176-185
27418777-1	2015	BACKGROUND: New Delhi metallo-beta-lactamase-1(NDM-1) is a novel type of metallo-beta-lactamase (MBL) which inactivates all beta-lactam antibiotics except aztreonam.	Aztreonam	155-164	NDM-1	Klebsiella pneumoniae	12-46
27418777-1	2015	BACKGROUND: New Delhi metallo-beta-lactamase-1(NDM-1) is a novel type of metallo-beta-lactamase (MBL) which inactivates all beta-lactam antibiotics except aztreonam.	Aztreonam	155-164	NDM-1	Klebsiella pneumoniae	47-52
27418777-1	2015	BACKGROUND: New Delhi metallo-beta-lactamase-1(NDM-1) is a novel type of metallo-beta-lactamase (MBL) which inactivates all beta-lactam antibiotics except aztreonam.	Aztreonam	155-164	hypothetical protein	Klebsiella pneumoniae	22-44
27418777-1	2015	BACKGROUND: New Delhi metallo-beta-lactamase-1(NDM-1) is a novel type of metallo-beta-lactamase (MBL) which inactivates all beta-lactam antibiotics except aztreonam.	Aztreonam	155-164	hypothetical protein	Klebsiella pneumoniae	97-100
32427286-0	2021	Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales.	Aztreonam	39-48	mannose-binding lectin family member 3, pseudogene	Homo sapiens	99-102
35453287-1	2022	Antimicrobial Activity of Aztreonam in Combination with Old and New beta-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections.	Aztreonam	26-35	mannose-binding lectin family member 3, pseudogene	Homo sapiens	102-105
2613337-5	1989	Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime.	Aztreonam	104-113	plexin domain containing 1	Homo sapiens	164-169
2613337-5	1989	Although all the extended broad spectrum enzymes described above hydrolyzed cefotaxime, ceftazidime and aztreonam, the four enzymes could be easily differentiated: TEM-3 hydrolyzed cefotaxime preferentially, TEM-5 and RHH-1 hydrolyzed ceftazidime approximately three times faster than cefotaxime, whereas TEM-10 hydrolyzed ceftazidime 42 times faster than cefotaxime.	Aztreonam	104-113	adhesion G protein-coupled receptor A2	Homo sapiens	208-213
2813957-0	1989	Effect of aztreonam on immunohistochemical localizations of cytochrome P-450 (M-1) in male rats.	Aztreonam	10-19	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-81
2506109-1	1989	TEM-7 is a novel broad-spectrum beta-lactamase (Bla), selected in vivo, with a resistance profile similar to that of TEM-1 and TEM-2, but extended to ceftazidime (Caz) and aztreonam.	Aztreonam	172-181	plexin domain containing 1	Homo sapiens	0-5
3104483-2	1987	For E. cloacae, pre-incubation with ceftriaxone, cefoxitin, cefamandole, cefoperazone, or imipenem produced significantly larger amounts of beta-lactamase than did pre-incubation with moxalactam, clavulanate, ceftazidime, or aztreonam.	Aztreonam	225-234	Beta lactamase	Pseudomonas aeruginosa	140-154
2721291-2	1989	A 1-gram single intravenous injection of aztreonam or carumonam yielded mean prostatic concentrations of 6.0 mg/kg in 20 patients.	Aztreonam	41-50	BCL2 related protein A1	Homo sapiens	0-3
2731449-8	1989	Aztreonam achieved good blood and CSF penetration and performed well in the treatment of 20 cases of H. influenzae meningitis and in the one case of S. heidelberg meningitis.	Aztreonam	0-9	colony stimulating factor 2	Homo sapiens	34-37
3117536-6	1987	Enzyme production in the aztreonam-resistant variants was identical to that in the wild-type strains with a single exception, where the entire derepression of beta-lactamase production in one of the variants took place.	Aztreonam	25-34	Beta lactamase	Pseudomonas aeruginosa	159-173
3509031-3	1987	Aztreonam showed good antibacterial activity even against Pseudomonas spp.	Aztreonam	0-9	histocompatibility minor 13	Homo sapiens	70-73
3566801-4	1987	In addition, Aztreonam was found to decrease the specific content of microsomal cytochrome P-450 in male rats but not in female rats.	Aztreonam	13-22	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	80-96
3566801-6	1987	Furthermore, the results of quantitation of P-450 (M-1), one of the male specific forms of cytochrome P-450, indicated that the administration of Aztreonam resulted in a dose-dependent decrease in the content of P-450 (M-1) in liver microsomes from male rats.	Aztreonam	146-155	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	91-107
3911882-3	1985	High production of cloned E. coli chromosomal beta-lactamase, however, provided resistance to cefamandole, cefoxitin, cefotaxime, ceftazidime, and aztreonam but not to BMY-28142 or imipenem.	Aztreonam	147-156	beta-lactamase	Escherichia coli	46-60
3834136-6	1985	Side effects possibly attributed to AZT were diarrhea in 2 cases and slight increase of GOT and GPT in 1 case, although they disappeared promptly afterward.	Aztreonam	36-39	glutamic--pyruvic transaminase	Homo sapiens	96-99
33595756-0	2021	Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae.	Aztreonam	90-99	hypothetical protein	Klebsiella pneumoniae	129-151
4094063-11	1985	The serum concentrations of AZT for a two-month-old patient with pyelonephritis were 65, 50, 35, 22.8 and 12.4 micrograms/ml at 1/2, 1, 2, 4 and 6 hours, respectively and T1/2 was 2.42 hours after injecting AZT 20 mg/kg by intravenous injection.	Aztreonam	28-31	angiotensin II receptor type 1	Homo sapiens	125-146
2934785-4	1985	Among aztreonam and control groups, three-fold increases in serum aspartate aminotransferase (SGOT) and serum alanine aminotransferase (SGPT) values occurred at comparably low frequencies; the mean values of SGOT and SGPT were slightly higher in patients administered aztreonam than in those given cefamandole.	Aztreonam	6-15	glutamic--pyruvic transaminase	Homo sapiens	110-134
2934786-5	1985	The only definite reactions attributable to aztreonam were asymptomatic increases in serum aspartate aminotransferase (SGOT) and serum alanine aminotransferase (SGPT) in four patients; none of these reactions interfered with completion of therapy.	Aztreonam	44-53	glutamic--pyruvic transaminase	Homo sapiens	135-159
33719123-7	2021	The ESBL-positives showed significantly higher resistance rates to gentamicin, co-trimoxazole, tetracycline, aztreonam, and chloramphenicol (P<0.05).	Aztreonam	109-118	EsbL	Escherichia coli	4-8
3833581-0	1985	[Renal tolerance of aztreonam evaluated on the basis of the urinary excretion of N-acetyl-beta-glucosaminidase].	Aztreonam	20-29	O-GlcNAcase	Homo sapiens	81-110
4040132-2	1985	Two to eight hours after a single 2 gm intravenous dose, CSF aztreonam levels ranged from 0.76 to 16.6 mg/l.	Aztreonam	61-70	colony stimulating factor 2	Homo sapiens	57-60
4040132-5	1985	Penetration of aztreonam into the CSF in the presence of meningeal inflammation appears adequate to warrant therapeutic trials in patients infected with susceptible organisms.	Aztreonam	15-24	colony stimulating factor 2	Homo sapiens	34-37
33367916-1	2021	BACKGROUND: Aztreonam/avibactam is a combination agent that shows promise in treating infections caused by highly antibiotic-resistant MBL-producing Enterobacterales.	Aztreonam	12-21	mannose-binding lectin family member 3, pseudogene	Homo sapiens	135-138
33367916-12	2021	These findings can help assure clinical and public health laboratories that testing of aztreonam/avibactam by BMD can act as a reliable surrogate test when the combination of ceftazidime/avibactam and aztreonam is being considered for treatment of highly antibiotic-resistant MBL-producing Enterobacterales.	Aztreonam	87-96	mannose-binding lectin family member 3, pseudogene	Homo sapiens	276-279
31424008-0	2019	Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study.	Aztreonam	32-41	OXA-48	Klebsiella pneumoniae	67-73
33276387-2	2021	Aztreonam/avibactam is under clinical development for treatment of serious infections caused by Gram-negative bacteria, including MBL-producers.	Aztreonam	0-9	mannose-binding lectin family member 3, pseudogene	Homo sapiens	130-133
33276387-12	2021	CONCLUSIONS: Our results support clinical development of aztreonam/avibactam to treat infections caused by Enterobacterales, including MBL-producers.	Aztreonam	57-66	mannose-binding lectin family member 3, pseudogene	Homo sapiens	135-138
31420947-1	2019	Aztreonam-avibactam (ATM-AVI) is a promising combination to treat serious infections caused by multidrug-resistant (MDR) pathogens.	Aztreonam	0-9	ATM serine/threonine kinase	Homo sapiens	21-24
33212285-0	2020	Aztreonam plus Ceftazidime-Avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteremia in a neutropenic patient: Last resort therapy?	Aztreonam	0-9	NDM-1	Klebsiella pneumoniae	53-58
33212285-2	2020	pneumoniae harboring NDM-1 in a neutropenic patient using aztreonam-ceftazidime-avibactam, who previously failed colistin and meropenem therapy.	Aztreonam	58-67	NDM-1	Klebsiella pneumoniae	21-26
33204124-17	2020	Conclusion: OXA-423, the first report of an amino acid substitution located at conserved active-site motifs of OXA-23, conferred lower MIC values of penicillins and carbapenems as compared with OXA-23, while without affecting the resistance profiles of expanded-spectrum cephalosporins and aztreonam.	Aztreonam	290-299	class D beta-lactamase OXA-23	Acinetobacter baumannii	111-117
33133036-8	2020	Compared to the KPC-2-producing strain, the KPC-55-producing strain exhibited a lower level of resistance to most beta-lactam drugs tested, however, the KPC-55 enzyme catalyzed aztreonam and meropenem at an increased efficiency compared to the catalytic activity of KPC-2.	Aztreonam	177-186	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	16-21
33133036-8	2020	Compared to the KPC-2-producing strain, the KPC-55-producing strain exhibited a lower level of resistance to most beta-lactam drugs tested, however, the KPC-55 enzyme catalyzed aztreonam and meropenem at an increased efficiency compared to the catalytic activity of KPC-2.	Aztreonam	177-186	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	266-271
31128287-6	2020	Four other plasmids containing 12 different resistance genes, including blaCTX-M-15 and strA/B, were introduced over time, providing additional resistance to aztreonam and streptomycin.	Aztreonam	158-167	CTX-M-15 beta-lactamase	Klebsiella pneumoniae	72-83
31128287-6	2020	Four other plasmids containing 12 different resistance genes, including blaCTX-M-15 and strA/B, were introduced over time, providing additional resistance to aztreonam and streptomycin.	Aztreonam	158-167	streptomycin phosphoTransferase	Klebsiella pneumoniae	88-94
31860667-1	2019	Pseudomonas aeruginosa, a main cause of human infection, can gain resistance to the antibiotic aztreonam through a mutation in NalD, a transcriptional repressor of cellular efflux.	Aztreonam	95-104	peroxisomal biogenesis factor 13	Homo sapiens	127-131
31860667-2	2019	Here we combine computational analysis of clinical isolates, transcriptomics, metabolic modeling and experimental validation to find a strong association between NalD mutations and resistance to aztreonam-as well as resistance to other antibiotics-across P. aeruginosa isolated from different patients.	Aztreonam	195-204	peroxisomal biogenesis factor 13	Homo sapiens	162-166
31860667-4	2019	Transcriptomics analysis confirmed the primary mechanism of NalD action-a loss-of-function mutation that caused constitutive overexpression of the MexAB-OprM efflux system-which lead to aztreonam resistance but, surprisingly, had no fitness cost in the absence of the antibiotic.	Aztreonam	186-195	peroxisomal biogenesis factor 13	Homo sapiens	60-64
31570403-3	2019	The objective of this study was to evaluate the in vitro activity and compare synergy between aztreonam in combination with ceftazidime-avibactam and meropenem-vaborbactam against serine and MBL-producing Enterobacteriaceae via time-kill analyses.	Aztreonam	94-103	hypothetical protein	Klebsiella pneumoniae	191-194
30782990-4	2019	VCC-1 hydrolyzes penicillins, cephalothin, aztreonam, and carbapenems and, like the broadly disseminated class A carbapenemase KPC-2, is only weakly inhibited by clavulanic acid or tazobactam.	Aztreonam	43-52	C-X-C motif chemokine ligand 17	Homo sapiens	0-5
30044946-1	2018	Ceftazidime/avibactam plus aztreonam (CZA+ATM) is an emerging option to combat carbapenemase-producing Enterobacteriaceae (CPE) expressing resistance via multiple beta-lactamases within Ambler classes A, B, C, and D. The benefit of this combination is apparent when the pathogen-specific resistance genotype is characterized.	Aztreonam	27-36	ATM serine/threonine kinase	Homo sapiens	42-45
30258039-8	2018	Lower MICs for ceftriaxone, cefepime, aztreonam, meropenem, and imipenem for the mutated KPC-2-producing isolates were observed compared to those of the isolates producing a wild-type KPC-2.	Aztreonam	38-47	KPC-2	Escherichia coli	89-94
29912337-12	2018	The isolate also carried blaCTX-M-55, which encodes an ESBL conferring resistance to aztreonam (which completed its resistance to all clinically available beta-lactams), and rmtB, which mediates high-level resistance to aminoglycosides, on an IncFII plasmid.	Aztreonam	85-94	Beta-lactamase CTX-M-55	Escherichia coli	25-36
29912337-12	2018	The isolate also carried blaCTX-M-55, which encodes an ESBL conferring resistance to aztreonam (which completed its resistance to all clinically available beta-lactams), and rmtB, which mediates high-level resistance to aminoglycosides, on an IncFII plasmid.	Aztreonam	85-94	EsbL	Escherichia coli	55-59
29553742-5	2018	We demonstrate this by studying deacylation and reverse acylation reactions of aztreonam drug catalyzed by a class-C beta lactamase (CBL) bacterial enzyme.	Aztreonam	79-88	Cbl proto-oncogene	Homo sapiens	109-131
29941651-0	2018	TEM-184, a Novel TEM-Derived Extended-Spectrum beta-Lactamase with Enhanced Activity against Aztreonam.	Aztreonam	93-102	beta-lactamase	Escherichia coli	47-61
29553742-5	2018	We demonstrate this by studying deacylation and reverse acylation reactions of aztreonam drug catalyzed by a class-C beta lactamase (CBL) bacterial enzyme.	Aztreonam	79-88	Cbl proto-oncogene	Homo sapiens	133-136
29553742-6	2018	Mechanistic details and nature of kinetics of aztreonam hydrolysis by CBL are elaborated here.	Aztreonam	46-55	Cbl proto-oncogene	Homo sapiens	70-73
29272413-0	2018	Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.	Aztreonam	77-86	NDM-1	Klebsiella pneumoniae	91-103
29336873-3	2018	However, existing first generation monobactam drugs like aztreonam have limited clinical utility against MBL-expressing strains because they are impacted by serine beta-lactamases (SBLs), which are often co-expressed in clinical isolates.	Aztreonam	57-66	mannose-binding lectin family member 3, pseudogene	Homo sapiens	105-108
29185411-1	2017	This descriptive and cross-sectional study was planned to determine the dilemma of inadvertent detection of extended spectrum beta lactamase (ESBL) production in Enterobacteriaceaewhen using inhibition zone size of antibiotic disks of Cefotaxime or Aztreonam in routine antibiotic susceptibility testing as recommended by Clinical Laboratory Standards Institute (CLSI).	Aztreonam	249-258	EsbL	Escherichia coli	108-140
29229762-3	2018	These substitutions cause OXA-239 to hydrolyze late-generation cephalosporins and the monobactam aztreonam with greater efficiency than OXA-23.	Aztreonam	97-106	class D beta-lactamase OXA-23	Acinetobacter baumannii	26-32
29046407-0	2018	An Improved Extended-Spectrum-beta-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.	Aztreonam	70-79	Beta lactamase	Pseudomonas aeruginosa	30-44
29029278-9	2017	Bacterial eradication of MRSA was 100% and 98.5% in the delafloxacin group and the vancomycin/aztreonam group, respectively.	Aztreonam	94-103	solute carrier family 9 member A6	Homo sapiens	25-29
29185411-1	2017	This descriptive and cross-sectional study was planned to determine the dilemma of inadvertent detection of extended spectrum beta lactamase (ESBL) production in Enterobacteriaceaewhen using inhibition zone size of antibiotic disks of Cefotaxime or Aztreonam in routine antibiotic susceptibility testing as recommended by Clinical Laboratory Standards Institute (CLSI).	Aztreonam	249-258	EsbL	Escherichia coli	142-146
27889371-5	2017	Analysis of blaSHV open-reading frame showed that blaSHV-5 had a high hydrolysis activity to the broad-spectrum penicillin (ampicillin or piperacillin), ceftazidime, ceftriaxone, cefotaxime and aztreonam.	Aztreonam	194-203	BlaSHV-5	Escherichia coli	50-58
28069651-6	2017	The hydrolysis of amoxicillin and nitrocefin by KPC-2 and CTX-M-15 was moderately affected by the substitution N132G, but that of ceftazidime, ceftaroline, and aztreonam was drastically reduced.	Aztreonam	160-169	UBA domain containing 1	Homo sapiens	48-53
27795378-4	2017	In these first reported structures of a class A beta-lactamase in an acyl-enzyme complex with aztreonam, we directly observed most of the hydrogen atoms (as deuterium) within the active site.	Aztreonam	94-103	amyloid beta precursor protein	Homo sapiens	46-52
26498989-10	2015	The aztreonam/avibactam combination demonstrates inhibitory activity against MBL-producing enteric bacteria owing to the stability of the monobactam to these enzymes, but resistance is still an issue for MBL-producing non-fermentative bacteria.	Aztreonam	4-13	mannose-binding lectin family member 3, pseudogene	Homo sapiens	77-80
26498989-10	2015	The aztreonam/avibactam combination demonstrates inhibitory activity against MBL-producing enteric bacteria owing to the stability of the monobactam to these enzymes, but resistance is still an issue for MBL-producing non-fermentative bacteria.	Aztreonam	4-13	mannose-binding lectin family member 3, pseudogene	Homo sapiens	204-207
26024868-1	2015	OBJECTIVES: The combination of aztreonam/avibactam has promising activity against MDR Gram-negative pathogens producing metallo-beta-lactamases (MBLs), such as New Delhi MBL-1.	Aztreonam	31-40	mannose-binding lectin (protein A) 1	Mus musculus	170-175
26055361-0	2015	Conformational Change Observed in the Active Site of Class C beta-Lactamase MOX-1 upon Binding to Aztreonam.	Aztreonam	98-107	mesenchyme homeobox 1	Homo sapiens	76-81
26055361-1	2015	We solved the crystal structure of the class C beta-lactamase MOX-1 complexed with the inhibitor aztreonam at 1.9A resolution.	Aztreonam	97-106	mesenchyme homeobox 1	Homo sapiens	62-67
26055361-3	2015	Surprisingly, compared to that in the structure of free MOX-1, this main-chain carboxyl changes its position significantly upon binding to aztreonam.	Aztreonam	139-148	mesenchyme homeobox 1	Homo sapiens	56-61